Added to YB: 2026-03-06
Pitch date: 2026-03-05
NVO [bullish]
Novo Nordisk A/S
Author Info
The Dutch Investors are a team of four seasoned, passionate inversores uncovering the world's top businesses. They bring you 52 in-depth stock analyses each year! Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products.
Market Cap
DKK 1.0T
Pitch Price
N/A
Price Target
N/A
Dividend
5.05%
EV/EBITDA
7.31
P/E
10.05
EV/Sales
3.66
Sector
Pharmaceuticals
Category
value
3 Stocks That Have NEVER Been Cheaper! - Novo Nordisk A/S
NVO: GLP-1 leader at historic low 9x EV/EBIT vs 40x mid-2024 peak. 2026 guide: -5% to -13% sales/op profit on CagriSema trial miss vs Lilly (20.2% vs 23.6% weight loss), 50% US price cuts to $675/mo, TrumpRx uncertainty. 80% gross margin, 100M+ US obesity market vs limited capacity. Oral Wegovy launched Jan 2026, expanding indications (heart failure, MASH). Bridge year mispriced vs long-term dominance.
Read full article (2 min)